Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Increased carotid artery wall stiffness and plaque prevalence in HIV infected patients measured with ultrasound elastography.

Roy Cardinal MH, Durand M, Chartrand-Lefebvre C, Fortin C, Baril JG, Trottier B, Routy JP, Soulez G, Tremblay C, Cloutier G.

Eur Radiol. 2020 Feb 12. doi: 10.1007/s00330-020-06660-9. [Epub ahead of print]

PMID:
32052172
2.

Eccentric versus conventional cycle training to improve muscle strength in advanced COPD: A randomized clinical trial.

Bourbeau J, De Sousa Sena R, Taivassalo T, Richard R, Jensen D, Baril J, Rocha Vieira DS, Perrault H.

Respir Physiol Neurobiol. 2020 Feb 9:103414. doi: 10.1016/j.resp.2020.103414. [Epub ahead of print]

PMID:
32050099
3.

Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.

Eron J, Hung CC, Baril JG, Slim J, Falcó V, Bogner J, Maggiolo F, Mills A, Sievers J, Man CY, Urbaityte R, Underwood M, Tenorio AR, Pappa KA, Wynne B, Koteff J, Gartland M, Smith KY, Aboud M.

J Acquir Immune Defic Syndr. 2020 Jan 16. doi: 10.1097/QAI.0000000000002302. [Epub ahead of print]

PMID:
31977595
4.

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate.

Huhn GD, Shamblaw DJ, Baril JG, Hsue PY, Mills BL, Nguyen-Cleary T, McCallister S, Das M.

Open Forum Infect Dis. 2019 Nov 11;7(1):ofz472. doi: 10.1093/ofid/ofz472. eCollection 2020 Jan.

5.

Use of Free-Living Step Count Monitoring for Heart Failure Functional Classification: Validation Study.

Baril JF, Bromberg S, Moayedi Y, Taati B, Manlhiot C, Ross HJ, Cafazzo J.

JMIR Cardio. 2019 May 17;3(1):e12122. doi: 10.2196/12122.

6.

Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs.

Zaidan SM, Leyre L, Bunet R, Larouche-Anctil E, Turcotte I, Sylla M, Chamberland A, Chartrand-Lefebvre C, Ancuta P, Routy JP, Baril JG, Trottier B, MacPherson P, Trottier S, Harris M, Walmsley S, Conway B, Wong A, Thomas R, Kaplan RC, Landay AL, Durand M, Chomont N, Tremblay CL, El-Far M; Canadian HIV and Aging Cohort Study.

J Acquir Immune Defic Syndr. 2019 Dec 15;82(5):503-513. doi: 10.1097/QAI.0000000000002185.

PMID:
31714430
7.

Circulating (1→3)-β-D-glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection.

Mehraj V, Ramendra R, Isnard S, Dupuy FP, Ponte R, Chen J, Kema I, Jenabian MA, Costinuik CT, Lebouché B, Thomas R, Coté P, Leblanc R, Baril JG, Durand M, Chartrand-Lefebvre C, Tremblay C, Ancuta P, Bernard NF, Sheppard DC, Routy JP; Montreal Primary HIV Infection Study and Canadian HIV and Aging Cohort Study Groups .

Clin Infect Dis. 2020 Jan 2;70(2):232-241. doi: 10.1093/cid/ciz212.

PMID:
30877304
8.

CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection.

Mehraj V, Ramendra R, Isnard S, Dupuy FP, Lebouché B, Costiniuk C, Thomas R, Szabo J, Baril JG, Trottier B, Coté P, LeBlanc R, Durand M, Chartrand-Lefebvre C, Kema I, Zhang Y, Finkelman M, Tremblay C, Routy JP.

Front Immunol. 2019 Feb 21;10:289. doi: 10.3389/fimmu.2019.00289. eCollection 2019.

9.

Smoke-induced neuromuscular junction degeneration precedes the fibre type shift and atrophy in chronic obstructive pulmonary disease.

Kapchinsky S, Vuda M, Miguez K, Elkrief D, de Souza AR, Baglole CJ, Aare S, MacMillan NJ, Baril J, Rozakis P, Sonjak V, Pion C, Aubertin-Leheudre M, Morais JA, Jagoe RT, Bourbeau J, Taivassalo T, Hepple RT.

J Physiol. 2018 Jul;596(14):2865-2881. doi: 10.1113/JP275558. Epub 2018 May 19.

10.

Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital.

Windle SB, Dehghani P, Roy N, Old W, Grondin FR, Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, Cassavar D, Dion D, Haught H, Mehta SR, Baril JF, Lambert C, Madan M, Abramson BL, Eisenberg MJ; EVITA Investigators.

CMAJ. 2018 Mar 26;190(12):E347-E354. doi: 10.1503/cmaj.170377.

11.

Socio-economic status and time trends associated with early ART initiation following primary HIV infection in Montreal, Canada: 1996 to 2015.

Mehraj V, Cox J, Lebouché B, Costiniuk C, Cao W, Li T, Ponte R, Thomas R, Szabo J, Baril JG, Trottier B, Côté P, LeBlanc R, Bruneau J, Tremblay C, Routy JP; Montreal Primary HIV-Infection Study Group.

J Int AIDS Soc. 2018 Feb;21(2). doi: 10.1002/jia2.25034.

12.

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis.

Tan DHS, Hull MW, Yoong D, Tremblay C, O'Byrne P, Thomas R, Kille J, Baril JG, Cox J, Giguere P, Harris M, Hughes C, MacPherson P, O'Donnell S, Reimer J, Singh A, Barrett L, Bogoch I, Jollimore J, Lambert G, Lebouche B, Metz G, Rogers T, Shafran S; Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network.

CMAJ. 2017 Nov 27;189(47):E1448-E1458. doi: 10.1503/cmaj.170494. No abstract available. Erratum in: CMAJ. 2018 Jun 25;190(25):E782.

13.

Pathways From HIV-Related Stigma to Antiretroviral Therapy Measures in the HIV Care Cascade for Women Living With HIV in Canada.

Logie CH, Lacombe-Duncan A, Wang Y, Kaida A, Conway T, Webster K, de Pokomandy A, Loutfy MR, Anema A, Becker D, Brotto L, Carter A, Cardinal C, Colley G, Ding E, Duddy J, Gataric N, Hogg RS, Hosward T, Jabbari S, Jones E, Kestler M, Langlois A, Lima V, Lloyd-Smith E, Medjuck M, Miller C, Money D, Nicholson V, Ogilvie G, Patterson S, Pick N, Roth E, Salters K, Sanchez M, Sas J, Sereda P, Summers M, Tom C, Wang L, Webster K, Zhang W, Abdul-Noor R, Angel J, Barry F, Bauer G, Beaver K, Benoit A, Bertozzi B, Borton S, Bourque T, Brophy J, Burchell A, Carlson A, Cioppa L, Cohen J, Conway T, Cooper C, Cotnam J, Cousineau J, Fraleigh A, Gagnier B, Gasingirwa C, Greene S, Hart T, Islam S, Kaushic C, Kennedy L, Kerr D, Kiboyogo M, Kwaramba G, Leonard L, Lewis J, Logie C, Margolese S, Muchenje M, Ndungʼu M, OʼBrien K, Ouellette C, Powis J, Quan C, Raboud J, Rachlis A, Ralph E, Rourke S, Rueda S, Sandre R, Smaill F, Smith S, Tigere T, Tharao W, Walmsley S, Wobeser W, Yee J, Yudin M, Baril JG, Burke NB, Clément P, Dayle J, Dubuc D, Fernet M, Groleau D, Hot A, Klein M, Martin C, Massie L, Ménard B, OʼBrien N, Otis J, Peltier D, Pierre A, Proulx-Boucher K, Rouleau D, Savoie É, Tremblay C, Trottier B, Trottier S, Tsoukas C, Gahagan J, Hankins C, Masching R, Ogunnaike-Cooke S.

J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):144-153. doi: 10.1097/QAI.0000000000001589.

14.

Limiting cardiovascular events associated with HIV and antiretroviral therapy.

Brenner BG, Baril JG.

AIDS. 2017 Nov 28;31(18):2551-2553. doi: 10.1097/QAD.0000000000001676. No abstract available.

PMID:
29120901
15.

The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol.

Durand M, Chartrand-Lefebvre C, Baril JG, Trottier S, Trottier B, Harris M, Walmsley S, Conway B, Wong A, Routy JP, Kovacs C, MacPherson PA, Monteith KM, Mansour S, Thanassoulis G, Abrahamowicz M, Zhu Z, Tsoukas C, Ancuta P, Bernard N, Tremblay CL; investigators of the Canadian HIV and Aging Cohort Study.

BMC Infect Dis. 2017 Sep 11;17(1):611. doi: 10.1186/s12879-017-2692-2.

16.

Smokers and Postcessation Weight Gain After Acute Coronary Syndrome.

Dehghani P, Habib B, Windle SB, Roy N, Old W, Grondin FR, Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, Cassavar D, Dion D, Haught H, Mehta SR, Baril JF, Lambert C, Madan M, Abramson BL, Eisenberg MJ.

J Am Heart Assoc. 2017 Apr 18;6(4). pii: e004785. doi: 10.1161/JAHA.116.004785.

17.

Eccentric Ergometer Training Promotes Locomotor Muscle Strength but Not Mitochondrial Adaptation in Patients with Severe Chronic Obstructive Pulmonary Disease.

MacMillan NJ, Kapchinsky S, Konokhova Y, Gouspillou G, de Sousa Sena R, Jagoe RT, Baril J, Carver TE, Andersen RE, Richard R, Perrault H, Bourbeau J, Hepple RT, Taivassalo T.

Front Physiol. 2017 Mar 3;8:114. doi: 10.3389/fphys.2017.00114. eCollection 2017.

18.

The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection.

Mehraj V, Jenabian MA, Ponte R, Lebouché B, Costiniuk C, Thomas R, Baril JG, LeBlanc R, Cox J, Tremblay C, Routy JP; Montreal Primary HIV Infection, the Canadian Long-Term Non-Progressors Study Groups.

AIDS. 2016 Jun 19;30(10):1617-27. doi: 10.1097/QAD.0000000000001105.

19.

Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors.

El-Far M, Kouassi P, Sylla M, Zhang Y, Fouda A, Fabre T, Goulet JP, van Grevenynghe J, Lee T, Singer J, Harris M, Baril JG, Trottier B, Ancuta P, Routy JP, Bernard N, Tremblay CL; Investigators of the Canadian HIV+ Slow Progressor Cohort.

Sci Rep. 2016 Mar 15;6:22902. doi: 10.1038/srep22902.

20.

Extended synaptotagmin interaction with the fibroblast growth factor receptor depends on receptor conformation, not catalytic activity.

Tremblay MG, Herdman C, Guillou F, Mishra PK, Baril J, Bellenfant S, Moss T.

J Biol Chem. 2016 Feb 12;291(7):3173. doi: 10.1074/jbc.A115.656918. No abstract available.

21.

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.

Baril JG, Angel JB, Gill MJ, Gathe J, Cahn P, van Wyk J, Walmsley S.

PLoS One. 2016 Feb 5;11(2):e0148231. doi: 10.1371/journal.pone.0148231. eCollection 2016. Review.

22.

Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Jacobson JM, Routy JP, Welles S, DeBenedette M, Tcherepanova I, Angel JB, Asmuth DM, Stein DK, Baril JG, McKellar M, Margolis DM, Trottier B, Wood K, Nicolette C.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):31-8. doi: 10.1097/QAI.0000000000000926.

23.

Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome.

Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, Cassavar D, Dion D, Haught H, Mehta SR, Baril JF, Lambert C, Madan M, Abramson BL, Dehghani P; EVITA Investigators.

Circulation. 2016 Jan 5;133(1):21-30. doi: 10.1161/CIRCULATIONAHA.115.019634. Epub 2015 Nov 9.

PMID:
26553744
24.

Reply.

Turcot A, Girard S, Courteau M, Baril J, Larcocque R.

Occup Med (Lond). 2015 Aug;65(6):505. No abstract available.

PMID:
26460401
25.

Addressing Assumptions for the Use of Non-invasive Cardiac Output Measurement Techniques During Exercise in COPD.

Perrault H, Richard R, Kapchinsky S, Baril J, Bourbeau J, Taivassalo T.

COPD. 2016;13(1):75-81. doi: 10.3109/15412555.2015.1043985. Epub 2015 Sep 25.

PMID:
26408087
26.

Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.

Cao W, Mehraj V, Trottier B, Baril JG, Leblanc R, Lebouche B, Cox J, Tremblay C, Lu W, Singer J, Li T, Routy JP; Montreal Primary HIV Infection Study Group, Vézina S, Charest L, Milne M, Huchet E, Lavoie S, Friedman J, Duchastel M, Villielm F, Côté P, Potter M, Lessard B, Charron MA, Dufresne S, Turgeon ME, Rouleau D, Labrecque L, Fortin C, de Pokomandy A, Hal-Gagné V, Munoz M, Deligne B, Martel-Laferrière V, Gilmore N, Fletcher M, Szabo J.

Clin Infect Dis. 2016 Jan 15;62(2):250-257. doi: 10.1093/cid/civ809. Epub 2015 Sep 8.

27.

Extended Synaptotagmin Interaction with the Fibroblast Growth Factor Receptor Depends on Receptor Conformation, Not Catalytic Activity.

Tremblay MG, Herdman C, Guillou F, Mishra PK, Baril J, Bellenfant S, Moss T.

J Biol Chem. 2015 Jun 26;290(26):16142-56. doi: 10.1074/jbc.M115.656918. Epub 2015 Apr 28. Erratum in: J Biol Chem. 2016 Feb 12;291(7):3173.

28.

Noise-induced hearing loss and combined noise and vibration exposure.

Turcot A, Girard SA, Courteau M, Baril J, Larocque R.

Occup Med (Lond). 2015 Apr;65(3):238-44. doi: 10.1093/occmed/kqu214. Epub 2015 Mar 10.

PMID:
25759070
29.

Immunosuppressive Tryptophan Catabolism and Gut Mucosal Dysfunction Following Early HIV Infection.

Jenabian MA, El-Far M, Vyboh K, Kema I, Costiniuk CT, Thomas R, Baril JG, LeBlanc R, Kanagaratham C, Radzioch D, Allam O, Ahmad A, Lebouché B, Tremblay C, Ancuta P, Routy JP; Montreal Primary infection and Slow Progressor Study Groups.

J Infect Dis. 2015 Aug 1;212(3):355-66. doi: 10.1093/infdis/jiv037. Epub 2015 Jan 23.

PMID:
25616404
30.

A significant reduction in the frequency of HIV-1 drug resistance in Québec from 2001 to 2011 is associated with a decrease in the monitored viral load.

Charest H, Doualla-Bell F, Cantin R, Murphy DG, Lemieux L, Brenner B, Hardy I, Moisi D, Lo E, Baril JG, Wainberg MA, Roger M, Tremblay C.

PLoS One. 2014 Oct 8;9(10):e109420. doi: 10.1371/journal.pone.0109420. eCollection 2014.

31.

Canadian consensus statement on HIV and its transmission in the context of criminal law.

Loutfy M, Tyndall M, Baril JG, Montaner JS, Kaul R, Hankins C.

Can J Infect Dis Med Microbiol. 2014 May;25(3):135-40.

32.

Kinetics of HIV-1 CTL epitopes recognized by HLA I alleles in HIV-infected individuals at times near primary infection: the Provir/Latitude45 study.

Papuchon J, Pinson P, Guidicelli GL, Bellecave P, Thomas R, LeBlanc R, Reigadas S, Taupin JL, Baril JG, Routy JP, Wainberg M, Fleury H; Provir/Latitude 45 study group.

PLoS One. 2014 Jun 25;9(6):e100452. doi: 10.1371/journal.pone.0100452. eCollection 2014.

33.

Cardiovascular disease mortality among retired workers chronically exposed to intense occupational noise.

Girard SA, Leroux T, Verreault R, Courteau M, Picard M, Turcotte F, Baril J, Richer O.

Int Arch Occup Environ Health. 2015 Jan;88(1):123-30. doi: 10.1007/s00420-014-0943-8. Epub 2014 May 3.

PMID:
24792922
34.

HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Tremblay C, Hardy I, Lalonde R, Trottier B, Tsarevsky I, Vézina LP, Roger M, Wainberg M, Baril JG.

Can J Infect Dis Med Microbiol. 2013 Winter;24(4):202-8.

35.

Falls risk and hospitalization among retired workers with occupational noise-induced hearing loss.

Girard SA, Leroux T, Verreault R, Courteau M, Picard M, Turcotte F, Baril J.

Can J Aging. 2014 Mar;33(1):84-91. doi: 10.1017/S0714980813000664. Epub 2013 Dec 17.

PMID:
24345605
36.
37.

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S; extended SPRING-2 Study Group.

Lancet Infect Dis. 2013 Nov;13(11):927-35. doi: 10.1016/S1473-3099(13)70257-3. Epub 2013 Sep 25.

PMID:
24074642
38.

Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.

Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H.

Clin Infect Dis. 2013 Nov;57(10):1489-96. doi: 10.1093/cid/cit529. Epub 2013 Aug 14.

PMID:
23946221
39.

Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up.

Laprise C, Baril JG, Dufresne S, Trottier H.

AIDS Patient Care STDS. 2013 Jul;27(7):378-86. doi: 10.1089/apc.2013.0009.

40.

Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir.

Fournier C, Higgins N, Thomas R, Baril JG, Thibeault D, Lalonde R, Sheehan NL.

Ther Drug Monit. 2013 Apr;35(2):264-9. doi: 10.1097/FTD.0b013e3182834057.

PMID:
23503454
41.

Design and implementation of a randomized crossover study of valproic acid and antiretroviral therapy to reduce the HIV reservoir.

Routy JP, Angel JB, Spaans JN, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sékaly RP, Tremblay CL.

HIV Clin Trials. 2012 Nov-Dec;13(6):301-7. doi: 10.1310/hct1306-301.

42.

Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up.

Laprise C, Baril JG, Dufresne S, Trottier H.

Clin Infect Dis. 2013 Feb;56(4):567-75. doi: 10.1093/cid/cis937. Epub 2012 Nov 9.

PMID:
23143096
43.

Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.

Klein MB, Baril JG, Charron MA, Fortin C, Lalonde R, Matte MF, Poliquin M, Talbot A, Therrien R, Tremblay C, Trottier B, Tsarevsky I, Villeneuve JP.

Can J Infect Dis Med Microbiol. 2011 Fall;22(3):88-96.

44.

Characteristics of the swallowing sounds recorded in the ear, nose and on trachea.

Sarraf-Shirazi S, Baril JF, Moussavi Z.

Med Biol Eng Comput. 2012 Aug;50(8):885-90. doi: 10.1007/s11517-012-0938-0. Epub 2012 Jul 18.

PMID:
22802141
45.

Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee.

Rouleau D, Fortin C, Trottier B, Lalonde R, Lapointe N, Côté P, Routy JP, Matte MF, Tsarevsky I, Baril JG.

Can J Infect Dis Med Microbiol. 2011 Summer;22(2):52-60.

46.

Risk of spontaneous intracranial hemorrhage in HIV-infected individuals: a population-based cohort study.

Durand M, Sheehy O, Baril JG, LeLorier J, Tremblay CL.

J Stroke Cerebrovasc Dis. 2013 Oct;22(7):e34-41. doi: 10.1016/j.jstrokecerebrovasdis.2012.03.014. Epub 2012 May 2.

PMID:
22554568
47.

Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.

Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sékaly RP, Boulassel MR.

HIV Med. 2012 May;13(5):291-6. doi: 10.1111/j.1468-1293.2011.00975.x. Epub 2012 Jan 26.

48.

Recognizing cognitive and psychiatric changes in the post-highly active antiretroviral therapy era.

Carvalhal A, Baril JG, Crouzat F, De Wet J, Junod P, Kovacs C, Sheehan N.

Can J Infect Dis Med Microbiol. 2012 Winter;23(4):209-15. Review.

49.

Eccentric cycle exercise in severe COPD: feasibility of application.

Rocha Vieira DS, Baril J, Richard R, Perrault H, Bourbeau J, Taivassalo T.

COPD. 2011 Aug;8(4):270-4. doi: 10.3109/15412555.2011.579926. Epub 2011 Jul 5.

PMID:
21728805
50.

Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.

Tremblay C, Trottier B, Rachlis A, Baril JG, Loutfy M, Lalonde R, Sampalis JS, Boulerice F.

HIV Clin Trials. 2011 May-Jun;12(3):151-60. doi: 10.1310/hct1203-151.

PMID:
21684855

Supplemental Content

Support Center